A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2002
10/17/2002	CA2442817A1 Implantation serine proteinases
10/17/2002	CA2442776A1 Antagonists of mcp-1 function and methods of use thereof
10/17/2002	CA2442739A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/17/2002	CA2442695A1 Indolinones substituted in the 6-position, the preparation thereof and their use as medicaments
10/17/2002	CA2442685A1 Estrogen receptor-related receptor alpha (err.alpha.) and cartilage formation
10/17/2002	CA2442683A1 Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
10/17/2002	CA2442605A1 Compounds and methods for inhibiting mrp1
10/17/2002	CA2442530A1 Compounds and methods for inhibiting mrp1
10/17/2002	CA2442315A1 Glycosaminoglycan/collagen complexes and use thereof
10/17/2002	CA2442141A1 Compounds and pharmaceutical compositions for inhibiting mrp1
10/17/2002	CA2442092A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
10/17/2002	CA2441941A1 Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth
10/17/2002	CA2441542A1 Method for preventing acute renal failure
10/17/2002	CA2441538A1 Stimulation of osteogenesis using rank ligand fusion proteins
10/17/2002	CA2440724A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	CA2440219A1 Proteins, polynucleotides encoding them and methods of using the same
10/17/2002	CA2440196A1 Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease
10/17/2002	CA2439109A1 Polyphenolics for enhancing endothelial cell-mediated fibrinolysis
10/17/2002	CA2435528A1 Novel polypeptides and nucleic acids encoded thereby
10/17/2002	CA2434693A1 Ionene polymers and their use as antimicrobial agents
10/16/2002	WO2001089505A1 Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
10/16/2002	WO2001079201A1 Process for preparation of sulfonamide derivatives and crystals thereof
10/16/2002	WO2001079186A1 2-guanidino-4-arylchinazolines as nhe-3 inhibitors
10/16/2002	EP1249451A2 Bicyclic-substituted 4-amino-pyridopyrimidine derivatives
10/16/2002	EP1249450A1 Benzimidazole derivatives
10/16/2002	EP1249246A1 Use of an histone deacetylase inhibitor for the treatment of diseases associated with an hpv infection
10/16/2002	EP1249245A1 Remedies and/or preventives for nervous system disorders
10/16/2002	EP1249240A1 Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
10/16/2002	EP1249239A1 Antipruritic agents for external use
10/16/2002	EP1249238A2 Topical pharmaceutical composition comprising betanechol
10/16/2002	EP1249237A1 Skin external agents and drugs
10/16/2002	EP1249236A1 ANTICANCER AGENTS, PERFUMES OR FOODS AND DRINKS CONTAINING $g(v)-HYDROXYFATTY ACIDS
10/16/2002	EP1249235A1 Remedies for hepatitis containing alanine and glycine
10/16/2002	EP1249234A1 Method of preventing retinopathy of prematurity in a neonate
10/16/2002	EP1249233A1 Npyy5 antagonists
10/16/2002	EP1249230A1 Microemulsion-preconcentrates and microemulsions comprising coenzyme Q10
10/16/2002	EP1248858A1 Antisense modulation of caspase 8 expression
10/16/2002	EP1248846A2 Human kinase protein and polynucleotides encoding the same
10/16/2002	EP1248841A2 Genes differentially expressed in breast cancer
10/16/2002	EP1248833A1 Therapeutic agent for ischemia which inhibits apoptosis under ischemic condition
10/16/2002	EP1248830A1 Antimicrobial compositions
10/16/2002	EP1248813A2 Antisense antibacterial cell division composition and method
10/16/2002	EP1248795A1 Antisense modulation of macrophage migration inhibitory factor expression
10/16/2002	EP1248794A1 Antisense modulation of smad7 expression
10/16/2002	EP1248792A1 Antisense modulation of peroxisome proliferator-activated receptor gamma expression
10/16/2002	EP1248791A1 Antisense modulation of caspase 3 expression
10/16/2002	EP1248787A2 Novel subtituted pyrazolo[4, 3-e]diazepines, pharmaceutical compositions containing them, use as medicinal products and processes for preparing them
10/16/2002	EP1248785A1 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
10/16/2002	EP1248784A1 Condensed azepines as vasopressin agonists
10/16/2002	EP1248783A1 Arylsulfonic acid salts of pyrimidine-based antiviral agents
10/16/2002	EP1248782A1 Anticancer compound and enantiomer separation method useful for synthesizing said compound
10/16/2002	EP1248781A1 Pyrazole cyclic amp-specific pde inhibitors
10/16/2002	EP1248779A2 Glycosidase ihhibitors and preparation thereof
10/16/2002	EP1248777A2 Tricyclic compounds with antiviral activity
10/16/2002	EP1248776A1 Semi-synthetic taxanes with antitumor and antiangiogenetic activities
10/16/2002	EP1248774A2 Polyhydroxystilbenes and stilbene oxides as antipsoriatic agents and protein kinase inhibitors
10/16/2002	EP1248771A1 Method for preparing hydroxypicolinic acid derivatives
10/16/2002	EP1248770A1 1,3,4-substituted piperidine analogs and uses thereof in treating addictions
10/16/2002	EP1248768A1 Bile acid-substituted phenyl-alkenoylguanidines, method for producing said phenyl-alkenoylguanidines, use thereof as medicaments or diagnostic reagents and medicaments containing the same
10/16/2002	EP1248763A2 Aromatic di-keto derivatives as glucose-6-phosphate translocase inhibitors
10/16/2002	EP1248761A1 Compounds which mimic the chemical and biological properties of discodermolide
10/16/2002	EP1248654A2 Intra-tumoral administration of il-12 encoding nucleic acid molecules
10/16/2002	EP1248652A2 Stable aqueous deoxyfructosazine solution
10/16/2002	EP1248651A1 Product comprising a heterotrimeric g protein signal transduction inhibitor associated with anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension
10/16/2002	EP1248638A2 Novel therapeutic use of enoxaparin
10/16/2002	EP1248637A1 Pharmaceutical composition comprising pectin effective in inhibiting the male reproductive toxicity
10/16/2002	EP1248636A1 Dextrin containing compositions for prevention of adhesions
10/16/2002	EP1248635A1 Antisense modulation of glycogen synthase kinase 3 alpha expression
10/16/2002	EP1248634A1 Antisense modulation of mekk2 expression
10/16/2002	EP1248633A1 Antisense modulation of glycogen synthase kinase 3 beta expression
10/16/2002	EP1248632A2 Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
10/16/2002	EP1248631A1 Methods for inhibiting/treating hiv infections and aids related symptoms
10/16/2002	EP1248630A1 Composition, in particular cosmetic or dermatological composition, containing oligosaccharides and preparation method and cosmetic treatment method
10/16/2002	EP1248629A1 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
10/16/2002	EP1248628A1 Phospholipid compositions as anti-inflammation agents
10/16/2002	EP1248627A2 Use of dehydroepiandrosterone, its precursors and derivatives, by oral administration, as hydrating agents with direct action
10/16/2002	EP1248626A2 Pharmaceutical compositions containing steroidal structures and uses thereof
10/16/2002	EP1248625A2 Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
10/16/2002	EP1248624A1 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS
10/16/2002	EP1248623A2 Treatment of diabetic ulcers
10/16/2002	EP1248622A1 Anxiety method
10/16/2002	EP1248621A1 Method and composition for the treatment of pain
10/16/2002	EP1248620A1 A new use of levosimendan
10/16/2002	EP1248619A1 Amorphous paroxetine compositon
10/16/2002	EP1248618A1 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- 2,3']bipyridinyl
10/16/2002	EP1248617A1 2-aza-bicyclo 2.2.2]octane nmda/nr2b antagonists
10/16/2002	EP1248616A2 Functional coating of linezolid microcapsules for oral administration
10/16/2002	EP1248615A1 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
10/16/2002	EP1248614A2 Non-peptide inhibition of t-lymphocyte activation and therapies related thereto
10/16/2002	EP1248613A1 Clonidine preparations
10/16/2002	EP1248612A1 Novel compounds and compositions as protease inhibitors
10/16/2002	EP1248611A1 Inhibition of two-component signal transduction systems
10/16/2002	EP1248610A2 Use of at least a fatty ester for preparing a composition designed to inhibit 5-alpha-reductase activity, in pharmacology, in particular dermatology, in cosmetics and as food additive
10/16/2002	EP1248609A1 Method of treating benign forgetfulness
10/16/2002	EP1248608A2 Substances for use in treating psoriasis
10/16/2002	EP1248607A1 Urotensin-ii receptor antagonists
10/16/2002	EP1248606A1 Use of fumaric acid derivatives for treating mitochondrial diseases
10/16/2002	EP1248605A2 Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
10/16/2002	EP1248604A2 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
10/16/2002	EP1248603A2 Use of particular compounds for prophylaxis and treatment of hepatitis c

1 ... 5679 5680 5681 5682 5683 5684 5685 5686 5687 5688 5689 5690 5691 5692 5693 5694 5695 5696 5697 5698 5699 ... 7860